m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02894)
Name
Enrofloxacin
Synonyms
Enrofloxacin; 93106-60-6; Baytril; Enrofloxacine; CFPQ; Enrofloxacinum; Enrofloxacino; endrofloxicin; BAY VP 2674; Bay-Vp-2674; Enrofloxacine [French]; Enrofloxacinum [Latin]; Enrofloxacino [Spanish]; UNII-3DX3XEK1BN; N-Ethylciprofloxacin; Baytril (TN); ERFX; Enrofloxacin [USAN:BAN:INN]; 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; HSDB 6952; 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 3DX3XEK1BN; Enrofloxacin (USAN/INN)
    Click to Show/Hide
Status
Preclinical
Structure
Formula
C19H22FN3O3
InChI
1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
InChIKey
SPFYMRJSYKOXGV-UHFFFAOYSA-N
PubChem CID
71188
VARIDT Drug ID
DR01565
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Enrofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enrofloxacin through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther. 2006 Aug;29(4):279-87.